Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy.
Buja
L Maximilian
LM
D001706:Biopsy; D002196:Capillaries / Q000737:chemistry / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D004699:Endocardium / Q000473:pathology*; D004730:Endothelium, Vascular / Q000737:chemistry / Q000473:pathology; D000795:Fabry Disease / Q000150:complications*; D006801:Humans; D002479:Inclusion Bodies / Q000737:chemistry / Q000648:ultrastructure; D008833:Microcirculation; D015337:Multicenter Studies as Topic; D032383:Myocytes, Cardiac / Q000378:metabolism / Q000473:pathology; D011994:Recombinant Proteins / Q000627:therapeutic use; D014281:Trihexosylceramides / Q000032:analysis / Q000378:metabolism; D000519:alpha-Galactosidase / Q000627:therapeutic use*
D011994:Recombinant Proteins; D014281:Trihexosylceramides; C018549:globotriaosylceramide; D000519:alpha-Galactosidase